Literature DB >> 28274950

MANAGEMENT OF ENDOCRINE DISEASE: Diagnostic and therapeutic approach of tall stature.

Edoarda V A Albuquerque1, Renata C Scalco2,3, Alexander A L Jorge1.   

Abstract

Tall stature is defined as a height of more than 2 standard deviations (s.d.) above average for same sex and age. Tall individuals are usually referred to endocrinologists so that hormonal disorders leading to abnormal growth are excluded. However, the majority of these patients have familial tall stature or constitutional advance of growth (generally associated with obesity), both of which are diagnoses of exclusion. It is necessary to have familiarity with a large number of rarer overgrowth syndromes, especially because some of them may have severe complications such as aortic aneurysm, thromboembolism and tumor predisposition and demand-specific follow-up approaches. Additionally, endocrine disorders associated with tall stature have specific treatments and for this reason their recognition is mandatory. With this review, we intend to provide an up-to-date summary of the genetic conditions associated with overgrowth to emphasize a practical diagnostic approach of patients with tall stature and to discuss the limitations of current growth interruption treatment options.
© 2017 European Society of Endocrinology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28274950     DOI: 10.1530/EJE-16-1054

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  12 in total

Review 1.  Klinefelter syndrome, insulin resistance, metabolic syndrome, and diabetes: review of literature and clinical perspectives.

Authors:  Andrea Salzano; Roberta D'Assante; Liam M Heaney; Federica Monaco; Giuseppe Rengo; Pietro Valente; Daniela Pasquali; Eduardo Bossone; Daniele Gianfrilli; Andrea Lenzi; Antonio Cittadini; Alberto M Marra; Raffaele Napoli
Journal:  Endocrine       Date:  2018-03-23       Impact factor: 3.633

Review 2.  Comprehensive genetic testing approaches as the basis for personalized management of growth disturbances: current status and perspectives.

Authors:  Danielle Christine Maria van der Kaay; Anne Rochtus; Gerhard Binder; Ingo Kurth; Dirk Prawitt; Irène Netchine; Gudmundur Johannsson; Anita C S Hokken-Koelega; Miriam Elbracht; Thomas Eggermann
Journal:  Endocr Connect       Date:  2022-10-10       Impact factor: 3.221

3.  Pseudoacromegaly: A Differential Diagnostic Problem for Acromegaly With a Genetic Solution.

Authors:  Per Dahlqvist; Rupert Spencer; Pedro Marques; Mary N Dang; Camilla A M Glad; Gudmundur Johannsson; Márta Korbonits
Journal:  J Endocr Soc       Date:  2017-07-14

Review 4.  Tall Stature: A Challenge for Clinicians.

Authors:  Beatriz Corredor; Mehul Dattani; Chiara Gertosio; Mauro Bozzola
Journal:  Curr Pediatr Rev       Date:  2019

5.  Etiology and Clinical Profile of Patients with Tall Stature: A Single-Center Experience.

Authors:  Alpesh Goyal; Viveka P Jyotsna; Arun K C Singh; Yashdeep Gupta; Rajesh Khadgawat
Journal:  Indian J Endocrinol Metab       Date:  2020-11-09

6.  Epiphysiodesis for the treatment of tall stature and leg length discrepancy.

Authors:  Madeleine Willegger; Markus Schreiner; Alexander Kolb; Reinhard Windhager; Catharina Chiari
Journal:  Wien Med Wochenschr       Date:  2021-03-18

7.  Decreased lymphocytes and increased risk for infection are common in endogenous pediatric Cushing syndrome.

Authors:  Christina Tatsi; Rebecca Boden; Ninet Sinaii; Meg Keil; Charalampos Lyssikatos; Elena Belyavskaya; Sergio D Rosenzweig; Constantine A Stratakis; Maya B Lodish
Journal:  Pediatr Res       Date:  2017-12-06       Impact factor: 3.756

8.  Coexisting pituitary and non-pituitary gigantism in the same family.

Authors:  Pedro Marques; David Collier; Ariel Barkan; Márta Korbonits
Journal:  Clin Endocrinol (Oxf)       Date:  2018-10-10       Impact factor: 3.478

9.  Anti-Müllerian hormone and letrozole levels in boys with constitutional delay of growth and puberty treated with letrozole or testosterone.

Authors:  E Kohva; T Varimo; H Huopio; S Tenhola; R Voutilainen; J Toppari; P J Miettinen; K Vaaralahti; J Viinamäki; J T Backman; M Hero; T Raivio
Journal:  Hum Reprod       Date:  2020-02-29       Impact factor: 6.918

10.  Gonadotropin Suppression for 7 Years After a Single Histrelin Implant for Precocious Puberty.

Authors:  Douglas Villalta; Jose B Quintos
Journal:  J Endocr Soc       Date:  2022-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.